Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit

L. Bengt van Rijssen, Bas G. Koerkamp, Maurice J. Zwart, Bert A. Bonsing, Koop Bosscha, Ronald M. van Dam, Casper H. van Eijck, Michael F. Gerhards, Erwin van der Harst, Ignace H. de Hingh, Koert P. de Jong, Geert Kazemier, Joost Klaase, Cornelis J. van Laarhoven, I. Quintus Molenaar, Gijs A. Patijn, Coen G. Rupert, Hjalmar C. van Santvoort, Joris J. Scheepers, George P. van der SchellingOlivier R. Busch, Marc G. Besselink*, Thomas L. Bollen, Marco J. Bruno, Geert Jan van Tienhoven, Arnold Norduyn, David P. Berry, Bobby Tingstedt, Jennifer F. Tseng, Christopher L. Wolfgang, Dutch Pancreatic Cancer Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background Auditing is an important tool to identify practice variation and ‘best practices’. The Dutch Pancreatic Cancer Audit is mandatory in all 18 Dutch centers for pancreatic surgery. Methods Performance indicators and case-mix factors were identified by a PubMed search for randomized controlled trials (RCT's) and large series in pancreatic surgery. In addition, data dictionaries of two national audits, three institutional databases, and the Dutch national cancer registry were evaluated. Morbidity, mortality, and length of stay were analyzed of all pancreatic resections registered during the first two audit years. Case ascertainment was cross-checked with the Dutch healthcare inspectorate and key-variables validated in all centers. Results Sixteen RCT's and three large series were found. Sixteen indicators and 20 case-mix factors were included in the audit. During 2014–2015, 1785 pancreatic resections were registered including 1345 pancreatoduodenectomies. Overall in-hospital mortality was 3.6%. Following pancreatoduodenectomy, mortality was 4.1%, Clavien–Dindo grade ≥ III morbidity was 29.9%, median (IQR) length of stay 12 (9–18) days, and readmission rate 16.0%. In total 97.2% of >40,000 variables validated were consistent with the medical charts. Conclusions The Dutch Pancreatic Cancer Audit, with high quality data, reports good outcomes of pancreatic surgery on a national level.

Original languageEnglish
Pages (from-to)919-926
Number of pages8
JournalHPB
Volume19
Issue number10
DOIs
Publication statusPublished - 1 Oct 2017

Cite this

van Rijssen, L. B., Koerkamp, B. G., Zwart, M. J., Bonsing, B. A., Bosscha, K., van Dam, R. M., van Eijck, C. H., Gerhards, M. F., van der Harst, E., de Hingh, I. H., de Jong, K. P., Kazemier, G., Klaase, J., van Laarhoven, C. J., Molenaar, I. Q., Patijn, G. A., Rupert, C. G., van Santvoort, H. C., Scheepers, J. J., ... Dutch Pancreatic Cancer Group (2017). Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. HPB, 19(10), 919-926. https://doi.org/10.1016/j.hpb.2017.06.010